TW202229337A - 犬抗體變異體 - Google Patents

犬抗體變異體 Download PDF

Info

Publication number
TW202229337A
TW202229337A TW110136032A TW110136032A TW202229337A TW 202229337 A TW202229337 A TW 202229337A TW 110136032 A TW110136032 A TW 110136032A TW 110136032 A TW110136032 A TW 110136032A TW 202229337 A TW202229337 A TW 202229337A
Authority
TW
Taiwan
Prior art keywords
igg
cdata
antibody
ser
constant domain
Prior art date
Application number
TW110136032A
Other languages
English (en)
Chinese (zh)
Inventor
莉莎 柏格倫
亨利 坎普斯
Original Assignee
美商碩騰服務公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商碩騰服務公司 filed Critical 美商碩騰服務公司
Publication of TW202229337A publication Critical patent/TW202229337A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW110136032A 2020-09-28 2021-09-28 犬抗體變異體 TW202229337A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063084241P 2020-09-28 2020-09-28
US63/084,241 2020-09-28

Publications (1)

Publication Number Publication Date
TW202229337A true TW202229337A (zh) 2022-08-01

Family

ID=78599123

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110136032A TW202229337A (zh) 2020-09-28 2021-09-28 犬抗體變異體

Country Status (17)

Country Link
US (1) US12612454B2 (OSRAM)
EP (1) EP4217384A2 (OSRAM)
JP (1) JP2023543262A (OSRAM)
KR (1) KR20230079148A (OSRAM)
CN (1) CN116438196A (OSRAM)
AR (1) AR123636A1 (OSRAM)
AU (1) AU2021349301A1 (OSRAM)
BR (1) BR112023005393A2 (OSRAM)
CA (1) CA3194936A1 (OSRAM)
CL (2) CL2023000878A1 (OSRAM)
CO (1) CO2023004102A2 (OSRAM)
EC (1) ECSP23030271A (OSRAM)
IL (1) IL301413A (OSRAM)
MX (1) MX2023003624A (OSRAM)
PE (1) PE20231374A1 (OSRAM)
TW (1) TW202229337A (OSRAM)
WO (1) WO2022067233A2 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022020944A2 (pt) * 2020-04-17 2022-12-27 Zoetis Services Llc Variantes de anticorpos caninos
EP4217384A2 (en) 2020-09-28 2023-08-02 Zoetis Services LLC Canine antibody variants
JP2025524441A (ja) * 2022-06-21 2025-07-30 ゾエティス・サービシーズ・エルエルシー イヌ科動物抗体変異体
EP4652197A1 (en) 2023-01-20 2025-11-26 Petmedix Ltd. Therapeutic antibodies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
WO2006031370A2 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP6629069B2 (ja) 2012-06-06 2020-01-15 ゾエティス・エルエルシー イヌ化抗ｎｇｆ抗体およびその方法
EP4124624A3 (en) 2013-12-20 2023-05-03 Intervet International B.V. Antibodies against canine pd-1
US20210388053A1 (en) * 2018-10-18 2021-12-16 Kindred Biosciences, Inc. Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use
JP2022513653A (ja) * 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
CN113227134A (zh) * 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体
SG11202106478UA (en) 2019-01-03 2021-07-29 Invetx Inc Compositions for increasing half-life of a therapeutic agent in canines and methods of use
BR112022020944A2 (pt) * 2020-04-17 2022-12-27 Zoetis Services Llc Variantes de anticorpos caninos
US20220119513A1 (en) 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
EP4217384A2 (en) 2020-09-28 2023-08-02 Zoetis Services LLC Canine antibody variants

Also Published As

Publication number Publication date
CN116438196A (zh) 2023-07-14
CA3194936A1 (en) 2022-03-31
US20240010716A1 (en) 2024-01-11
AU2021349301A1 (en) 2023-08-24
AR123636A1 (es) 2022-12-28
US12612454B2 (en) 2026-04-28
BR112023005393A2 (pt) 2023-04-25
IL301413A (en) 2023-05-01
CL2023000878A1 (es) 2023-10-20
JP2023543262A (ja) 2023-10-13
ECSP23030271A (es) 2023-07-31
KR20230079148A (ko) 2023-06-05
PE20231374A1 (es) 2023-09-07
CL2024000628A1 (es) 2024-07-19
WO2022067233A3 (en) 2022-05-27
EP4217384A2 (en) 2023-08-02
WO2022067233A2 (en) 2022-03-31
CO2023004102A2 (es) 2023-04-05
MX2023003624A (es) 2023-04-11

Similar Documents

Publication Publication Date Title
KR20230005156A (ko) 개과 항체 변이체
KR20210109587A (ko) 인간 il-4ra에 대한 항체 및 이의 용도
US20250026834A1 (en) Feline antibody variants
KR20230079148A (ko) 개과 항체 변이체
TW202233687A (zh) 貓抗體恆定區中之突變
JP2024505072A (ja) イヌ科動物抗体の定常領域における変異
TWI814094B (zh) 貓抗體變異體
RU2847183C1 (ru) Варианты собачьих антител
RU2846726C1 (ru) Варианты собачьих антител
RU2858900C2 (ru) Варианты кошачьих антител
RU2840969C1 (ru) Варианты кошачьих антител
RU2855157C1 (ru) Мутации в константных областях антител кошек
BR122024006370A2 (pt) Polipeptídeo, seu uso, composição farmacêutica, kit, igg modificada, vetor, célula isolada, molécula de fusão, e seu método de fabricação